SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Pembrolizumab Solid Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name : Pembrolizumab Solid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
Company : MSD
Kilsheelan
Clonmel Tipperary, IE
Telephone : 353-51-601000
E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Reproductive toxicity, Category 1B : H360D: May damage the unborn child.
Specific target organ toxicity - repeated exposure, Category 1 : H372: Causes damage to organs through prolonged or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

Signal word : Danger

Hazard statements :
H360D May damage the unborn child.
H372 Causes damage to organs through prolonged or repeated exposure.

Precautionary statements :
Prevention:
P201 Obtain special instructions before use.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
Pembrolizumab Solid Formulation

Hazardous components which must be listed on the label:
Pembrolizumab

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pembrolizumab</td>
<td>1374853-91-4</td>
<td></td>
<td></td>
<td>Repr. 1B; H360D STOT RE 1; H372 (Immune system)</td>
<td>&gt;= 20 - &lt; 30</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection,
and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled:
- If inhaled, remove to fresh air.
- Get medical attention.

In case of skin contact:
- In case of contact, immediately flush skin with soap and plenty of water.
- Remove contaminated clothing and shoes.
- Get medical attention.
- Wash clothing before reuse.
- Thoroughly clean shoes before reuse.

In case of eye contact:
- If in eyes, rinse well with water.
- Get medical attention if irritation develops and persists.

If swallowed:
- If swallowed, DO NOT induce vomiting.
- Get medical attention.
- Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks:
- May damage the unborn child.
- Causes damage to organs through prolonged or repeated exposure.
- Contact with dust can cause mechanical irritation or drying of the skin.
- Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment:
- Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
- None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting:
- Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
5.3 Advice for firefighters

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions: Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Do not eat, drink or smoke when using this product.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types:
- Strong oxidizing agents
- Organic peroxides
- Explosives
- Gases

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pembrolizumab</td>
<td>1374853-91-4</td>
<td>TWA</td>
<td>75 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:
# Pembrolizumab Solid Formulation

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histidine</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>83,38 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>236,45 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>20,56 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>118,2 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>11,8 mg/kg bw/day</td>
</tr>
</tbody>
</table>

## Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histidine</td>
<td>Fresh water</td>
<td>0.1 mg/l</td>
</tr>
<tr>
<td></td>
<td>Freshwater - intermittent</td>
<td>1 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.01 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water - intermittent</td>
<td>1 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>20.5 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>0.392 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>0.039 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>0.02 mg/kg dry weight (d.w.)</td>
</tr>
</tbody>
</table>

## 8.2 Exposure controls

### Engineering measures
Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
If sufficient ventilation is unavailable, use with local exhaust ventilation.

### Personal protective equipment

#### Eye protection
Wear the following personal protective equipment:
- Safety goggles
- Equipment should conform to NS EN 166

#### Hand protection
Material: Chemical-resistant gloves

Remarks: Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

#### Skin and body protection
Select appropriate protective clothing based on chemical re-
Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to EN 143.

Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state</td>
<td>powder</td>
</tr>
<tr>
<td>Colour</td>
<td>white to off-white</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity, dynamic</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>No data available</td>
</tr>
<tr>
<td>Water solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
</tbody>
</table>
Relative density : No data available
Density : No data available
Relative vapour density : No data available
Particle characteristics
Particle size : No data available

9.2 Other information
Explosives : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Evaporation rate : No data available
Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Pembrolizumab Solid Formulation

Acute toxicity
Not classified based on available information.

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
May damage the unborn child.

Components:
Pembrolizumab:
Reproductive toxicity - Assessment
May damage the unborn child., Based on data from similar materials

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Causes damage to organs through prolonged or repeated exposure.

Components:
Pembrolizumab:
Target Organs:
Assessment
Immune system
Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:
Pembrolizumab:
Species: Monkey
NOAEL: 200 mg/kg
Application Route: Intravenous
Exposure time: 180 d
Remarks: No significant adverse effects were reported
Pembrolizumab Solid Formulation

Species: Dog
NOAEL: 200 mg/kg
Application Route: Intravenous
Exposure time: 180 d
Remarks: No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product: Pembrolizumab
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components: Pembrolizumab
Inhalation: Target Organs: Immune system
Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhoea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest., May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis
Remarks: Damage to fetus possible

SECTION 12: Ecological information

12.1 Toxicity
No data available

12.2 Persistence and degradability
No data available

12.3 Bioaccumulative potential
No data available

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment

Product: Pembrolizumab
Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of
Pembrolizumab Solid Formulation

12.6 Other adverse effects

**Product:**
Endocrine disrupting potential

- The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

- **Product:** Dispose of in accordance with local regulations.

  According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.

  Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

- **Contaminated packaging:** Empty containers should be taken to an approved waste handling site for recycling or disposal.

  If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

- Not regulated as a dangerous good

14.2 UN proper shipping name

- Not regulated as a dangerous good

14.3 Transport hazard class(es)

- Not regulated as a dangerous good

14.4 Packing group

- Not regulated as a dangerous good

14.5 Environmental hazards

- Not regulated as a dangerous good

14.6 Special precautions for user

- Not applicable

14.7 Maritime transport in bulk according to IMO instruments

  **Remarks:** Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

- **REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances:** Not applicable
preparations and articles (Annex XVII)
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).
REACH - List of substances subject to authorisation (Annex XIV)
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer
Regulation (EU) 2019/1021 on persistent organic pollutants (recast)
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals
Not applicable

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H360D: May damage the unborn child.
H372: Causes damage to organs through prolonged or repeated exposure if swallowed.

Full text of other abbreviations
Repr.: Reproductive toxicity
STOT RE: Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada);
Pembrolizumab Solid Formulation

Version 3.4  Revision Date: 18.05.2021  SDS Number: 530838-00012  Date of last issue: 09.04.2021
Date of first issue: 23.02.2016

Further information

Classification of the mixture:
Repr. 1B H360D Calculation method
STOT RE 1 H372 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NO / EN